{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:27:39Z","timestamp":1793730459781,"version":"4.6.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"U.S. Department of Veterans Affairs Special Purpose Medical Service funding","award":["SP80DPE.1-0160"],"award-info":[{"award-number":["SP80DPE.1-0160"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Calcitonin gene-related peptide (CGRP) is involved in migraine pathophysiology and blood pressure regulation. Although clinical trials have established the cardio-cerebrovascular safety profile of anti-CGRP treatment, limited high-quality real-world evidence exists on its long-term effects on blood pressure (BP). To address this gap, we examined the safety of anti-CGRP treatment on BP in patients with migraine headache in the Veterans Health Administration (VHA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We emulated a target trial of patients who initiated anti-CGRP treatment or topiramate for migraine prevention between May 17th, 2018 and February 28th, 2023. We calculated stabilized inverse probability weights to balance between groups and then used weighted linear mixed-effect models to estimate the systolic and diastolic BP changes over the study period. For patients without hypertension at baseline, we estimated the cumulative incidence of hypertension using Kaplan\u2013Meier curve. We also used weight mixed-effect Poisson model to estimate the number of antihypertension medications for patients with hypertension at baseline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This analysis included 69,589 patients and 554,437 blood pressure readings. of these, 18,880 patients received anti-CGRP treatment, and they were more likely to be women, have a chronic migraine diagnosis and higher healthcare utilization than those received topiramate. Among patients without hypertension at baseline, we found no significant differences in systolic BP changes over the four-year follow-up between anti-CGRP (slope [standard error, SE]\u2009=\u20090.48[0.06]) and topiramate treated patients (slope[SE]\u2009=\u20090.39[0.04]). The incidence of hypertension was similar for anti-CGRP and topiramate group (4.4 vs 4.3 per 100 person-years). Among patients with hypertension at baseline who initiated anti-CGRP treatment, we found a small but persistent effect on exacerbating hypertension during the first four years of treatment, as evidenced by a significant annual 3.7% increase in the number of antihypertensive medications prescribed (RR\u2009=\u20091.037, 95%CI 1.025\u20131.048).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggest that anti-CGRP treatment is safe regarding blood pressure in patients without hypertension. However, for those with baseline hypertension, anti-CGRP treatment resulted in a small but persistent increase in the number of antihypertensives, indicating an exacerbation of hypertension. Future studies are needed to evaluate the cardio-cerebrovascular safety of anti-CGRP treatment beyond the first four years.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-023-01640-y","type":"journal-article","created":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T08:01:46Z","timestamp":1692086506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Trajectory of blood pressure after initiating anti-calcitonin gene-related peptide treatment of migraine: a target trial emulation from the veterans health administration"],"prefix":"10.1186","volume":"24","author":[{"given":"Kaicheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda T.","family":"Fenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinh X.","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander B.","family":"Guirguis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Skanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason J.","family":"Sico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,15]]},"reference":[{"issue":"1","key":"1640_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1161\/01.HYP.35.1.470","volume":"35","author":"PR Gangula","year":"2000","unstructured":"Gangula PR, Zhao H, Supowit SC et al (2000) Increased blood pressure in \u03b1-calcitonin gene\u2013related peptide\/calcitonin gene knockout mice. Hypertension 35(1):470\u2013475","journal-title":"Hypertension"},{"issue":"12","key":"1640_CR2","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1161\/CIRCRESAHA.119.315429","volume":"125","author":"T Skaria","year":"2019","unstructured":"Skaria T, Mitchell KJ, Vogel O, W\u00e4lchli T, Gassmann M, Vogel J (2019) Blood pressure normalization-independent cardioprotective effects of endogenous, physical activity-induced \u03b1CGRP (\u03b1 Calcitonin Gene-Related Peptide) in chronically hypertensive mice. Circ Res 125(12):1124\u20131140","journal-title":"Circ Res"},{"issue":"3","key":"1640_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/0333102418821662","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW (2019) CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia 39(3):445\u2013458","journal-title":"Cephalalgia"},{"issue":"1","key":"1640_CR4","doi-asserted-by":"publisher","first-page":"033310242211282","DOI":"10.1177\/03331024221128250","volume":"43","author":"BC Klein","year":"2023","unstructured":"Klein BC, Miceli R, Severt L et al (2023) Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial. Cephalalgia 43(1):03331024221128250","journal-title":"Cephalalgia"},{"issue":"5","key":"1640_CR5","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, Goadsby PJ, Reuter U et al (2021) Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28(5):1716\u20131725","journal-title":"Eur J Neurol"},{"issue":"9","key":"1640_CR6","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1111\/head.14208","volume":"61","author":"DW Dodick","year":"2021","unstructured":"Dodick DW, Tepper SJ, Ailani J et al (2021) Risk of hypertension in erenumab\u2010treated patients with migraine: Analyses of clinical trial and postmarketing data. Headache 61(9):1411\u20131420","journal-title":"Headache"},{"issue":"1","key":"1640_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/head.14051","volume":"61","author":"S Saely","year":"2021","unstructured":"Saely S, Croteau D, Jawidzik L, Brinker A, Kortepeter C (2021) Hypertension: a new safety risk for patients treated with erenumab. Headache 61(1):202\u2013208","journal-title":"Headache"},{"key":"1640_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-019-1585-y","volume":"20","author":"ME Bangs","year":"2020","unstructured":"Bangs ME, Kudrow D, Wang S et al (2020) Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies. BMC Neurol 20:1\u201318","journal-title":"BMC Neurol"},{"issue":"6","key":"1640_CR9","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/head.13534","volume":"59","author":"SD Silberstein","year":"2019","unstructured":"Silberstein SD, McAllister P, Ning X et al (2019) Safety and tolerability of fremanezumab for the prevention of migraine: a pooled analysis of phases 2b and 3 clinical trials. Headache 59(6):880\u2013890","journal-title":"Headache"},{"issue":"10268","key":"1640_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D et al (2021) Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet 397(10268):51\u201360","journal-title":"Lancet"},{"issue":"9","key":"1640_CR11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","volume":"19","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Dodick DW, Ailani J et al (2020) Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial. Lancet Neurol 19(9):727\u2013737","journal-title":"Lancet Neurol"},{"issue":"17","key":"1640_CR12","doi-asserted-by":"publisher","first-page":"e1897","DOI":"10.1212\/WNL.0000000000201008","volume":"99","author":"LS de Vries","year":"2022","unstructured":"de Vries LS, van der Arend BW, VanDenBrink AM, Terwindt GM (2022) Blood pressure in patients with migraine treated with monoclonal anti-CGRP (Receptor) antibodies: a prospective follow-up study. Neurology 99(17):e1897\u2013e1904","journal-title":"Neurology"},{"issue":"18","key":"1640_CR13","doi-asserted-by":"publisher","first-page":"e1979","DOI":"10.1212\/WNL.0000000000200888","volume":"99","author":"EK Seng","year":"2022","unstructured":"Seng EK, Fenton BT, Wang K et al (2022) Frequency, demographics, comorbidities, and health care utilization by veterans with migraine: a VA nationwide cohort study. Neurology 99(18):e1979\u2013e1992","journal-title":"Neurology"},{"key":"1640_CR14","unstructured":"Department of Veterans Affairs and Department of Defense. VA\/DoD Clinical Practice Guideline for the Primary Care Management of Headache. https:\/\/www.healthquality.va.gov\/guidelines\/pain\/headache\/VADoDHeadacheCPGFinal508.pdf. Accessed 14th Mar 2023"},{"issue":"1","key":"1640_CR15","doi-asserted-by":"publisher","first-page":"e2034059","DOI":"10.1001\/jamanetworkopen.2020.34059","volume":"4","author":"L Min","year":"2021","unstructured":"Min L, Ha J-K, Aubert CE et al (2021) A method to quantify mean hypertension treatment daily dose intensity using health care system data. JAMA Netw Open 4(1):e2034059\u2013e2034059","journal-title":"JAMA Netw Open"},{"issue":"19","key":"1640_CR16","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS et al (2018) 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American heart association task force on clinical practice guidelines. J Am Coll Cardiol 71(19):e127\u2013e248","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1640_CR17","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1212\/WNL.0000000000008743","volume":"94","author":"D Kudrow","year":"2020","unstructured":"Kudrow D, Pascual J, Winner PK et al (2020) Vascular safety of erenumab for migraine prevention. Neurology 94(5):e497\u2013e510","journal-title":"Neurology"},{"issue":"10","key":"1640_CR18","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1016\/S2666-7568(22)00186-6","volume":"3","author":"YY Tan","year":"2022","unstructured":"Tan YY, Papez V, Chang WH, Mueller SH, Denaxas S, Lai AG (2022) Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England. The Lancet Healthy Longevity 3(10):e674\u2013e689","journal-title":"The Lancet Healthy Longevity"},{"key":"1640_CR19","doi-asserted-by":"publisher","first-page":"e25818","DOI":"10.7554\/eLife.25818","volume":"6","author":"M Maciejewski","year":"2017","unstructured":"Maciejewski M, Lounkine E, Whitebread S et al (2017) Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets. Elife 6:e25818","journal-title":"Elife"},{"issue":"9","key":"1640_CR20","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1161\/HYPERTENSIONAHA.122.19315","volume":"79","author":"JD Spence","year":"2022","unstructured":"Spence JD, Grosser T, FitzGerald GA (2022) Acetaminophen, nonsteroidal anti-inflammatory drugs, and hypertension. Hypertension 79(9):1922\u20131926","journal-title":"Hypertension"},{"key":"1640_CR21","doi-asserted-by":"publisher","first-page":"215013272096368","DOI":"10.1177\/2150132720963680","volume":"11","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Shewale AS, Lipton RB et al (2020) Migraine patients with cardiovascular disease and contraindications: an analysis of real-world claims data. J Prim Care Community Health 11:2150132720963680","journal-title":"J Prim Care Community Health"},{"issue":"12","key":"1640_CR22","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1161\/STR.0000000000000046","volume":"45","author":"JF Meschia","year":"2014","unstructured":"Meschia JF, Bushnell C, Boden-Albala B et al (2014) Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke 45(12):3754\u20133832","journal-title":"Stroke"},{"issue":"11","key":"1640_CR23","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA et al (2019) 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Circulation 140(11):e596\u2013e646","journal-title":"Circulation"},{"issue":"6","key":"1640_CR24","doi-asserted-by":"publisher","first-page":"107140","DOI":"10.1016\/j.jstrokecerebrovasdis.2023.107140","volume":"32","author":"G Arling","year":"2023","unstructured":"Arling G, Miech EJ, Myers LJ, Sexson A, Bravata DM (2023) The impact of the COVID-19 pandemic on blood pressure control after a stroke or transient ischemic attack among patients at VA medical centers. J Stroke Cerebrovasc Dis 32(6):107140","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"12","key":"1640_CR25","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1093\/aje\/kwaa124","volume":"189","author":"RK Ross","year":"2020","unstructured":"Ross RK, Breskin A, Westreich D (2020) When is a complete-case approach to missing data valid? The importance of effect-measure modification. Am J Epidemiol 189(12):1583\u20131589","journal-title":"Am J Epidemiol"},{"key":"1640_CR26","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","volume":"11","author":"M\u00c1 Hern\u00e1n","year":"2000","unstructured":"Hern\u00e1n M\u00c1, Brumback B, Robins JM (2000) Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11:561\u2013570","journal-title":"Epidemiology"},{"key":"1640_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","volume":"79","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Sauer BC, Hern\u00e1ndez-D\u00edaz S, Platt R, Shrier I (2016) Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol 79:70\u201375","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"1640_CR28","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/acn3.197","volume":"2","author":"CS Walker","year":"2015","unstructured":"Walker CS, Eftekhari S, Bower RL et al (2015) A second trigeminal CGRP receptor: function and expression of the AMY 1 receptor. Ann Clin Translatl Neurol 2(6):595\u2013608","journal-title":"Ann Clin Translatl Neurol"},{"issue":"6","key":"1640_CR29","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/ana.26072","volume":"89","author":"H Ghanizada","year":"2021","unstructured":"Ghanizada H, Al-Karagholi MAM, Walker CS et al (2021) Amylin analog pramlintide induces migraine-like attacks in patients. Ann Neurol 89(6):1157\u20131171","journal-title":"Ann Neurol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01640-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01640-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01640-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T13:02:08Z","timestamp":1700398928000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01640-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,15]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1640"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01640-y","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,15]]},"assertion":[{"value":"15 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research & Development Committee of the VHA Connecticut Healthcare System and was granted a waiver of informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}